Case report

Tuberculosis-induced acute respiratory distress syndrome treated with venovenous extracorporeal membrane oxygenation

Nguyen Gia Binh, Toshie Manabe, Dao Xuan Co, Pham The Thach, Dang Quoc Tuan, Bui Van Cuong, Le Thi Diem Tuyet, Koichiro Kudo, Nguyen Quoc Anh

A B S T R A C T

Tuberculosis (TB) is a rare but known cause of acute respiratory distress syndrome (ARDS) with a high mortality. Venovenous extracorporeal membrane oxygenation (VV-ECMO) may be an alternative option for treating TB-induced ARDS. However, the literature on TB-induced ARDS treated with VV-ECMO is limited and the most of them were prolonged therapy. We report on a 48-year-old man with TB-induced ARDS who was successfully treated by short-term use of VV-ECMO (5 days). He was developed symptoms and hospitalized with severe dyspnea in a local hospital for 3 days before admission to our hospital. At the time when he was transferred to our hospital, his chest computed tomography showed bilateral, diffuse and consolidative shadows all over the lungs, the ratio of partial pressure of arterial oxygen to the fraction of inspired oxygen (PaO2/FiO2) was 50 mmHg, and respiratory system compliance was 12.5 mL/cmH2O. Two days after admission, Mycobacterium tuberculosis was detected by a sputum smear examination and he was diagnosed with TB-induced ARDS. VV-ECMO support was then initiated with administration of anti-TB drugs and systemic corticosteroid treatment. On the 4th day of ECMO support, his PaO2/FiO2 increased to 400 mmHg and lung compliance increased to 45 mL/cmH2O. He was weaned from ECMO on the 5th day of ECMO support and was extubated at the 8th day. He was discharged from hospital on the 47th hospitalized day and continued anti-TB medication at home. VV-ECMO is effective for TB-induced ARDS even in short-term administration if progression of ARDS is rapid.

1. Introduction

Acute respiratory distress syndrome (ARDS) is an acute diffuse lung injury associated with a predisposing risk factor [1]. Despite adequate supplemental oxygenation, hypoxemia usually occurs in patients with ARDS [2,3]. Currently, several methods for treating ARDS have been proposed, including a lung protective ventilation strategy, prone positioning, and cytokine removal with hemodialysis. Venovenous extracorporeal membrane oxygenation (VV-ECMO) is also an option for treating ARDS and refractory hypoxic respiratory failure. VV-ECMO helps maintain oxygenation, allows the lungs to rest with a low tidal volume, and decreases the risk of ventilator-associated lung injury.

Pulmonary tuberculosis (TB) is an uncommon cause of ARDS [4] and the mortality of ARDS due to TB ranges between 60% and 90% [5]. As well as pulmonary TB, TB-induced ARDS slowly improves and may require long-term treatment. Several cases of TB-induced ARDS with prolonged VV-ECMO have been reported [6-8]. However, the effectiveness of VV-ECMO on TB-induced ARDS has not yet been determined. We report a patient with TB-induced ARDS who was successfully rescued by short-term use of VV-ECMO.

2. Case presentation

A 48-year-old man was admitted to a national tertiary hospital in Hanoi, Vietnam, with fever, cough, and shortness of breath. The patient was a member of medical staff in a TB hospital in the northeastern part of Vietnam. Four days before admission to our hospital, he had a fever, cough, and sputum. He was administered amoxicillin 2 g/day in his hospital. In the next day, his condition deteriorated and he developed dyspnea. In the next day, he visited and was hospitalized in a local general hospital, and was diagnosed with bacterial pneumonia. He was started to support with non-invasive mechanical ventilation (3 days
prior to the admission to our hospital) and treated with Ceftriaxone (2 g/day). However, his respiratory condition deteriorated. At that time, computed tomography (CT) scans showed bilateral diffuse consolidation (Fig. 1a). He had diabetes mellitus, chronic gout, and long-term use of corticosteroids.

At the time of admission to the emergency department in our hospital, a physical examination showed that the patient's body temperature was 38.5 °C and blood pressure was 100/60 mmHg. Arterial blood gas analysis showed that the ratio of partial pressure of arterial oxygen to the fraction of inspired oxygen (PaO2/FiO2) was 50 mmHg and lung compliance was 12 mL/cmH2O (Table 1). Laboratory findings at the time of admission were shown in Table 2. After the admission of the patient, he was transferred to the intensive care unit (ICU).

Upon arrival at the ICU, he had a blood pressure of 110/60 mmHg, heart rate of 102 beats/min, Oxygen saturation (SpO2) of 80%, central venous pressure of 10 mmHg, and Murray score for lung injury [10] of 4. A chest X-ray showed bilateral infiltration (Fig. 2a). A lung ultrasound examination showed no pleural fluid. At the same day, Mycobacterium tuberculosis was detected in a sputum smear for acid-fast bacteria (AFB + + +). Human immunodeficiency virus was not detected in the blood using the real-time polymerase chain reaction. Based on these physical examination, laboratory findings, chest images, and respiratory conditions, he was diagnosed with TB-induced ARDS. The discussion among the healthcare team was made to proceed to VV-ECMO. VV-ECMO was then initiated with internal jugular and femoral access vein cannulation by the Seldinger technique [11], with blood flow at 4.5 L/min and gas flow at 4.2 L/min. The mechanical ventilator setting and parameters were as follows: tidal volume (Vt), 4 mL/kg; end inspiratory plateau pressure (Pplat), < 25 cmH2O; respiratory rate (RR), 8 breaths/min, positive end-expiratory pressure (PEEP), 14 cmH2O, and FiO2 1.0. Anti-TB regimens were also initiated with ethambutol (1600 mg), pyrazinamide (1500 mg), and rifampicin/isoniazid (600 mg/400 mg). Regarding the administrations of antibiotics, Levofloxacin (750 mg) were administered for the first 3 days, then meropenem (1000 mg) and amikacin (1000 mg) were administered for 14 days [12]. Corticosteroids (100 mg of hydrocortisone/h) was also administered. In terms of anticoagulation regimen, heparin was applied for preventing the development of thrombosis at oxygenation membrane. The 100 IU/kg of dose of intravenous bolus dose was given when cannulas insertions were finished, then 10 IU/kg/hour as the maintaining dose. Activated Partial Thromboplastin Time was tested every 4–6 hours for monitoring heparin anticoagulation effect and was kept from 45 to 55 seconds. The patient had no any bleeding and oxygenation membrane was maintained well in the process.

After initiation of ECMO support, the patient’s hypoxemia rapidly improved to 216 mmHg of PaO2/FiO2 and lung compliance was improved to 26 mL/cmH2O on the 2nd day of ECMO support (Fig. 3). Chest radiography gradually improved on the 4th day of ECMO support (Fig. 2b and c). On the 5th day of ECMO support, the patient was weaned from ECMO, and PaO2/FiO2 and lung compliance were improved to > 390 mmHg and 38 mL/cmH2O, respectively (Fig. 3). The

Table 1
Changes in arterial blood gases and ventilatory parameters.

|            | pre-ECMO | ECMO Day 1 | ECMO Day 2 | ECMO Day 3 | ECMO Day 4 | ECMO Day 5 | ECMO weaning Day 6 | Post-ECMO Day 7 | Post-ECMO Day 8 | Extubation Day 8 |
|------------|----------|------------|------------|------------|------------|------------|-------------------|-----------------|-----------------|-----------------|
| pH         | 7.28     | 7.49       | 7.33       | 7.47       | 7.50       | 7.46       | 7.39              | 7.41            | 7.41            |
| PaCO2 (mmHg) | 42       | 35         | 51         | 45         | 35         | 37         | 32                | 33              | 33              |
| PaO2 (mmHg)  | 50       | 137        | 87         | 156        | 153        | 157        | 213               | 164             | 103             |
| Ventilation mode | VCV      | VCV       | VCV        | VCV        | VCV        | VCV        | VCV               | VCV             | PCV             |
| Respiration rate, breaths/min | 20       | 10         | 10         | 10         | 16         | 20         | 14                | 14              | 14              |
| FiO2 (mmHg)   | 100      | 100        | 40         | 50         | 40         | 50         | 40                | 40              | 40              |
| PaO2/FiO2 (mmHg) | 50       | 171        | 200        | 260        | 392        | 420        | 426               | 410             | 260             |
| Tidal volume (mL) | 380.0   | 300.0      | 250.0      | 250.0      | 250.0      | 360.0      | 400.0             | NA              | NA              |
| Plateau pressure (cmH2O) | NA       | 23.0       | 20.0       | 20.0       | 20.0       | 20.0       | NA                | NA              | NA              |
| PEEP (cmH2O)  | 10.0     | 10.0       | 14.0       | 14.0       | 10.0       | 14.0       | 8.0               | 5.0             | 5.0             |
| lungcompliance (mL/cmH2O) | 12.5     | 22.5       | 26.0       | 35.3       | 35.0       | 38.0       | 42.0              | NA              | NA              |

ECMO, extracorporeal membrane oxygenation; PaCO2, partial pressure of carbon dioxide; PaO2, partial pressure of arterial oxygen; FiO2, arterial oxygen to fraction of inspired oxygen; PEEP, positive end-expiratory pressure; VCV, volume control ventilation; PCV, pressure control ventilation; BiPAP, Biphasic Positive Airway pressure.

NA denotes not available.
patient was extubated at the 8th day after admission for ECMO. On the 10th day after admission for ECMO, mechanical ventilation support was backed because of respiratory muscle weakness caused by corticosteroid-induced myopathy. A cerebrospinal fluid examination was normal. On the 15th day, tracheostomy was performed. On the 35th day, the patient was weaned from mechanical ventilation and discharged on the 47th day. Anti-TB regimens were continued after discharge from hospital.

3. Discussion

This report shows successful treatment for the short-term use of VV-ECMO in ARDS caused by TB infection. While the use of ECMO is extensive and expensive, the present case demonstrated the possible role of VV-ECMO in the short term for treating TB-induced ARDS, especially if it is in the early stage.

| Table 2 | Changes in laboratory findings. |
|---------|----------------------------------|
| pre-ECMO | ECMO Day 1 | ECMO Day 2 | ECMO Day 3 | ECMO Day 4 | ECMO weaning Day 5 | Post-ECMO Day 6 | Post-ECMO Day 7 | Extubation Day 8 |
| WBC (× 1000/μl) | 11.4 | 3.54 | 5.76 | 6.4 | 7.1 | 7.3 | 7.27 | 12.25 | 9.7 |
| RBC (T/l) | 3.53 | 2.49 | 3.86 | 3.3 | 3.28 | 3.20 | 3.4 | 3.84 | 3.44 |
| Hemoglobin (g/l) | 186 | 72 | 106 | 97 | 95 | 93 | 89 | 108 | 96 |
| PT (× 1000/μl) | 254 | 188 | NA | 58 | 32 | NA | 34 | 46 | 27 |
| ALT (U/L) | 127 | 92 | NA | 38 | 35 | NA | 23 | 24 | 22 |
| Creatinine (mg/dl) | 1.19 | 139 | 119 | 140 | 165 | NA | 161 | 132 | 112 |
| INR | 1.07 | 1.16 | 0.98 | 1.09 | 1.11 | 1.11 | 1.22 | 1.13 | 1.22 |
| APTT (sec.) | 37 | 54 | 46 | 41.5 | 36.2 | 34 | 36 | 35.2 | 34.4 |
| Fibrinogen (g/L) | 4.5 | 6.4 | 1.29 | 7.58 | 6.8 | 6.8 | 7.16 | 7.33 | 7.38 |
| DIC score | 1 | 2 | 1 | 1 | 1 | 0 | 0 | 0 | 0 |

ECMO, extracorporeal membrane oxygenation; WBC, white blood cell count; RBC, red blood cell count; Plt, platelet count; AST, aspartate aminotransferase; ALT, alanine aminotransferase; INR, international normalized ratio; APTT, activated partial thromboplastin time; DIC, Disseminated Intravascular Coagulation. NA denotes not available.

TB-induced ARDS is rare, but its mortality is high because of a lack of established effective treatment methods [4, 5]. The present case had severe ARDS at the time of admission and his chest CT already showed diffuse consolidative shadows all over the lungs in a local hospital before admission to our hospital. However, there were only 4 days from development of symptoms, including fever, cough, and dyspnea. On the 2nd day after admission to hospital, Mycobacterium tuberculosis was detected in his sputum specimens with no other pathogens. Until that time, the patient did not realize that he had TB infection, even though he was in a high-risk population as a member of medical staff in a TB hospital and he used to abuse corticosteroids for the pain relief caused by gout attack. He also had diabetes mellitus. Drug regimens for TB infection were started together with conventional mechanical ventilation for treating ARDS. However, his PaO2/FiO2 decreased to 50 mmHg. We expect that improvement from a severe pulmonary condition caused by TB infection requires long-term pharmacotherapy. We initiated VV-ECMO.
ECMO together with conventional mechanical ventilation that may provide effective support, particularly in patients with severe lung injury at 2 days after admission to hospital, which was on the 5th day from disease onset. VV-ECMO has become an important method for treating ARDS [13]. After initiation of VV-ECMO, our patient’s hypoxemia and decreased lung compliance rapidly improved. He was weaned from ECMO after 5 days of support with ECMO. Previous reports on successful treatment of VV-ECMO in TB-induced ARDS focused on prolonged use [6–8,14]. The duration of use of VV-ECMO in previous studies was 36 [6], 52 [7], and 89 [8,15] days. In the recent report, a patient with miliary TB-induced ARDS on ECMO therapy without ventilator weaned from ECMO after 50 days [13]. In the present case, the pathophysiology of TB may be disseminated, since the onset of clinical symptoms, including dyspnea, was acute, and CT images of disease onset showed diffuse consolidation shadows in both lungs without focal signs at the initial stage. In addition, a report of patient with ARDS and septic-induced cardiomyopathy secondary to pulmonary TB with the veno-veno-arterial (VVA) ECMO indicated that blood gas exchange was recovered slowly, while cardiac function was recovered within 10 days from the initiation of VVA-ECMO and the patient weaned ECMO at 28 days [16]. This result inferred the difficulty of recovering the respiratory function for patient with TB if the lung destruction has been occurred [16]. However, the present case had the less lung destruction. A previous report showed that the association of disseminated TB with ARDS which presents the pathology of diffuse alveolar damage (DAD) was uncommon [2]. DAD was found in 7/196 cases of disseminated TB [2]. Generally, ARDS with the pathology of DAD has a poor prognosis [17]. Even use of ECMO in the early stage of ARDS does not result in a better prognosis than that with no use of ECMO [13]. In the present case, ARDS rapidly improved after using VV-ECMO. Only 5 days of ECMO treatment resulted in successful weaning. Therefore, pathophysiological condition on this patient may not yet organized DAD. Although TB requires long-term therapy, the difference of pathophysiology in ARDS in this case from inherent pathology of TB might be another reason for the short-term improvement in ECMO therapy.

The present case was treated with multiple medications, including anti-TB drugs, antibiotics, and corticosteroids. A previous case report indicated that high-dose steroid therapy for pulmonary TB contributed to a decreased requirement for long-term steroid use [7]. However, evidence for the effect of corticosteroids on ARDS due to disseminated TB is still lacking [15]. Any pharmacotherapy used in the present case did not appear to contribute to the rapid improvement. VV-ECMO should be considered as a treatment option for TB-induced ARDS, and it is effective, even in short-term administration, especially if TB shows rapid progression.

4. Conclusions

We report successful treatment of TB-induced ARDS with the short time use of VV-ECMO together with conventional ventilation and medications, including anti-TB drugs. VV-ECMO is effective for TB-induced ARDS even in short-term administration if progression of ARDS is rapid and if DAD has not organized. The difference of pathophysiology in ARDS from inherent pathology of TB might be the another reason for the short-term improvement in ECMO therapy. VV-ECMO should be considered as a supporting method to accelerate improvement of respiratory function in TB-induced ARDS. This case report warrants the further study.

Acknowledgements

We thank Ellen Knapp, PhD, from Edanz Group for editing a draft of this manuscript.

Appendix

ARDS Acute respiratory distress syndrome
TB tuberculosis
VV-ECMO Veno-venous extracorporeal membrane oxygenation
PaO2/FiO2 the ratio
CT computed tomography
DAD diffuse alveolar damage

Ethics approval and consent to participate

This study was approved by the Institutional Review Board of Bach Mai hospital. Written informed consent was obtained by the patient.

Availability of data and material

All data supporting the findings is contained within the manuscript.

Consent for publication

The patient provided written informed consent for the publication of this report.
Conflicts of interest

The authors declare that they have no competing interests.

Funding

The study was supported by the Emerging/re-emerging infectious disease project on the Japan Agency for Medical Research and Development (AMED): 18FY2018. The funders had no role in the design, methods, participant recruitment, data collection, analysis, and preparation of the paper.

Authors’ contributions

Conceived and designed the experiments: NGB, TM and KK. Performed experiments NGB, DXC, LDT, PTT, DQT and BVCKY. Analysed data: TM. Interpreted study results: NGB, TM, NGB, DXC, LDT, PTT, DQT, BVCKY, KK and NQA. Wrote the first draft of manuscript: TM. All authors read and approved the final manuscript.

References

[1] ARDS Definition Task Force, V.M. Ranieri, G.D. Rubenfeld, B.T. Thompson, N.D. Ferguson, E. Caldwell, et al., Acute respiratory distress syndrome: the Berlin definition, J. Am. Med. Assoc. 307 (23) (2012) 2526–2533.
[2] S. Sharma, U. Nahar, A. Das, B. Radotra, K. Joshi, S. Varma, R.K. Vasishta, Acute respiratory distress syndrome in disseminated tuberculosis: an uncommon association, Int. J. Tuberc. Lung Dis. 20 (2) (2016) 271–275.
[3] P. Befort, P. Corne, S. Godreuil, B. Jung, O. Jonquet, Clinical review of eight patients with acute respiratory distress syndrome due to pulmonary tuberculosis, Scand. J. Infect. Dis. 44 (3) (2012) 222–224.
[4] M.R. Pieling, E. Fan, Therapies for refractory hypoxemia in acute respiratory distress syndrome, J. Am. Med. Assoc. 304 (22) (2010) 2521–2527.
[5] R.D. Stapleton, B.M. Wang, L.D. Hudson, G.D. Rubenfeld, E.S. Caldwell, K.P. Steinberg, Causes and timing of death in patients with ARDS, Chest 128 (2) (2005) 525–532.
[6] M. Andersen, P. Tapia, M. Mercado, G. Bugedo, S. Bravo, T. Regueira, Catastrophic respiratory failure from tuberculosis pneumonia: survival after prolonged extracorporeal membrane oxygenation support, Respir Med Case Rep 10 (2013) 19–22.
[7] N. Omote, Y. Konoh, H. Taniguchi, T. Kimura, K. Kataoka, R. Hasegawa, V. Hasegawa, Acute respiratory distress syndrome due to severe pulmonary tuberculosis treated with extracorporeal membrane oxygenation: a case report and review of the literature, Respir Med Case Rep 19 (2016) 31–33.
[8] V. Cogliandro, G. Lapidula, A. Bandera, A. Muscatello, R. Marcolin, C. Abbuzzese, et al., ECMO: an alternative support for acute respiratory failure caused by tuberculosis? Int. J. Tuberc. Lung Dis. 18 (7) (2014 Jul) 879–881, https://doi.org/10.5588/ijtld.13.0752.
[9] Acute Respiratory Distress Syndrome Network, R.G. Brower, M.A. Matthay, A. Morris, D. Schoenfeld, B.T. Thompson, et al., Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome, N. Engl. J. Med. 342 (18) (2000) 1301–1308.
[10] J.F. Murray, M.A. Matthay, J.M. Luxe, M.R. Flick, An expanded definition of the adult respiratory distress syndrome, Am. Rev. Respir. Dis. 138 (1988) 720–723.
[11] S.I. Selldinger, Catheter replacement of the needle in percutaneous arteriography; a new technique, Acta Radiol. 39 (5) (1953) 368–376.
[12] A. Combes, D. Hajage, G. Capellier, A. Demoule, S. Lavoué, C. Guervilly, et al., EOLIA Trial Group, REVA, ECMONet, Extracorporeal membrane oxygenation for severe acute respiratory distress syndrome, N. Engl. J. Med. 378 (21) (2018) 1965–1975.
[13] A.C. Kahl, M.I. Metensky, M. Klompas, J. Muscedere, D.A. Sweeney, L.B. Palmer, et al., Management of adults with hospital-acquired and ventilator-associated pneumonia: 2016 clinical practice guidelines by the infectious diseases society of America and the American thoracic society, Clin. Infect. Dis. 63 (5) (2016) e61–e111.
[14] T. Mauri, G. Foti, A. Zanella, M. Bombino, A. Confalonieri, N. Patroniti, et al., Long-term extracorporeal membrane oxygenation with minimal ventilatory support: a new paradigm for severe ARDS? Minerva Anestesiol. 78 (3) (2012) 385–389.
[15] E. Vesteinsdottir, G. Myrdal, K.O. Sverrisson, S.J. Skarphedinsdottir, O. Gudlaugsdottir, S. Karason, ARDS from miliary tuberculosis successfully treated with ECMO, Respir Med Case Rep 26 (2019) 165–167.
[16] S.I. Lee, H.J. Hwang, S.Y. Lee, C.H. Choi, C.H. Park, K.Y. Park, et al., Veno-venoarterial extracorporeal membrane oxygenation for acute respiratory distress syndrome with septic-induced cardiomyopathy due to severe pulmonary tuberculosis, J. Artif. Organs 20 (4) (2017) 359–364.
[17] A.W. Thille, O. Peñuelas, J.A. Lorente, P. Fernández-Segoviano, J.M. Rodriguez, J.A. Aramburu, et al., Predictors of diffuse alveolar damage in patients with acute respiratory distress syndrome: a retrospective analysis of clinical autopsies, Crit. Care 21 (1) (2017) 254.